Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures
OI 2022 Presentation Highlights
NOV004 is a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. By improving fracture site accumulation and retention, NOV004 stimulates a robust healing response in preclinical studies of healthy normal, diabetic, osteoporotic, and OI in vivo models. During its OI 2022 presentation titled “Fracture-targeted Anabolics for Treatment of Osteogenesis Imperfecta Fractures,” the company highlighted several preclinical results demonstrating the efficacy of NOV004 in fractures induced in the OI in vivo experiments, including:
- High affinity to bone fractures: NOV004 was prepared by synthesizing an abaloparatide-like peptide conjugated to a hydroxyapatite-homing acidic oligopeptide to create a high affinity to bone fractures. While systemically administered in a distal spot from the fracture, NOV004 accumulates locally at the fracture site to improve the specificity of anabolics to fractures.
- Increased retention at the fractured site: NOV004 demonstrated a marked increase in retention at the fracture site with a 10-fold increase in AUC compared with non-targeted drug at the fracture site.
- Increased Bone Strength: Mechanical testing yielded a significant increase in force to fracture in the NOV004 over the vehicle control groups.
Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “will,” “can,” “may,” “should,” “estimate,” “project,” “potential,” “encouraged,” “positioned,” or other similar words. Examples of forward-looking statements include, among others, clinical development and strategic development path for NOV004; the company’s plans to pursue the strategic expansion of its development pipeline; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004 and advance to a lead indication; and the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety, and efficacy of the company’s product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the